Rapid7 Incorporated (NASDAQ:RPD) had a decrease of 40.49% in short interest. RPD’s SI was 649,500 shares in January as released by FINRA. Its down 40.49% from 1.09M shares previously. With 205,200 avg volume, 3 days are for Rapid7 Incorporated (NASDAQ:RPD)’s short sellers to cover RPD’s short positions. The SI to Rapid7 Incorporated’s float is 3.9%. The stock increased 0.92% or $0.2 during the last trading session, reaching $21.92. About 75,773 shares traded. Rapid7, Inc. (NASDAQ:RPD) has risen 56.77% since January 19, 2017 and is uptrending. It has outperformed by 40.07% the S&P500.
Cormorant Asset Management Llc decreased Portola Pharmaceuticals Inc (PTLA) stake by 44.44% reported in 2017Q3 SEC filing. Cormorant Asset Management Llc sold 400,000 shares as Portola Pharmaceuticals Inc (PTLA)’s stock rose 22.73%. The Cormorant Asset Management Llc holds 500,000 shares with $27.02M value, down from 900,000 last quarter. Portola Pharmaceuticals Inc now has $3.23B valuation. The stock decreased 0.30% or $0.15 during the last trading session, reaching $49.54. About 401,582 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since January 19, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.
Rapid7, Inc. provides security data and analytics solutions that enable organizations to implement an analytics-driven approach to cyber security and IT operations. The company has market cap of $961.87 million. It offers threat exposure management solutions, including Nexpose, which enables clients to assess and remediate their exposure to cyber risk; Metasploit, a penetration testing software solution; and AppSpider, an application security testing solution. It currently has negative earnings. The firm also provides incident detection and response solutions, such as InsightIDR, a cloud based offering for incident detection and response; Managed Detection and Response, a managed service, which provides clients with attacker behavior analytics, machine learning algorithms, and threat intelligence to hunt attackers; and incident response services that provide clients with access to security experts and experience.
Among 13 analysts covering Rapid7 (NASDAQ:RPD), 12 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Rapid7 had 32 analyst reports since August 11, 2015 according to SRatingsIntel. On Friday, August 26 the stock rating was initiated by Rosenblatt with “Buy”. As per Wednesday, December 13, the company rating was maintained by Rosenblatt. The stock of Rapid7, Inc. (NASDAQ:RPD) earned “Buy” rating by RBC Capital Markets on Wednesday, November 8. The rating was upgraded by Susquehanna to “Positive” on Tuesday, August 8. Northland Capital maintained the stock with “Buy” rating in Thursday, October 5 report. The firm has “Overweight” rating given on Thursday, February 11 by Barclays Capital. As per Friday, July 14, the company rating was maintained by Northland Capital. Cowen & Co maintained it with “Buy” rating and $2200 target in Friday, June 16 report. The company was maintained on Sunday, August 20 by RBC Capital Markets. KeyBanc Capital Markets maintained Rapid7, Inc. (NASDAQ:RPD) rating on Thursday, August 31. KeyBanc Capital Markets has “Buy” rating and $25.0 target.
Investors sentiment increased to 2.16 in 2017 Q3. Its up 0.85, from 1.31 in 2017Q2. It is positive, as 20 investors sold PTLA shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Polar Llp reported 588,200 shares. Hall Laurie J Trustee reported 190 shares. Nicholas Ptnrs Limited Partnership reported 0.24% stake. Sg Americas Securities stated it has 0% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Qs Investors Limited Liability invested in 0% or 2,611 shares. Temasek Hldg (Private) Ltd reported 4.88M shares or 1.54% of all its holdings. 2.40M were accumulated by State Street. Manufacturers Life Insur Com The accumulated 41,900 shares. Nationwide Fund Advisors owns 62,176 shares or 0.01% of their US portfolio. Art Ltd Llc invested in 0.15% or 55,700 shares. Hartwell J M Lp holds 35,450 shares or 0.37% of its portfolio. Weiss Multi, Alabama-based fund reported 10,000 shares. Tortoise Ltd Liability Corp has invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Price T Rowe Associate Md holds 0% or 26,950 shares. Rothschild Investment Il has 20,880 shares.
Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals had 33 analyst reports since August 5, 2015 according to SRatingsIntel. Credit Suisse maintained the shares of PTLA in report on Tuesday, December 27 with “Outperform” rating. Morgan Stanley maintained the stock with “Buy” rating in Monday, June 26 report. The firm earned “Neutral” rating on Friday, August 19 by Citigroup. Morgan Stanley maintained the shares of PTLA in report on Friday, October 6 with “Overweight” rating. The firm has “Buy” rating by Cowen & Co given on Monday, June 26. Oppenheimer maintained the shares of PTLA in report on Friday, August 4 with “Buy” rating. The firm earned “Buy” rating on Monday, June 26 by Citigroup. The firm has “Outperform” rating given on Thursday, August 24 by Credit Suisse. The company was downgraded on Tuesday, May 31 by Credit Suisse. Oppenheimer maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Monday, January 15 with “Buy” rating.
Since December 15, 2017, it had 0 insider purchases, and 1 insider sale for $563,950 activity. 12,000 Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) shares with value of $563,950 were sold by Wolff Henry Ward.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.